Kliniken Essen-Mitte

Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) (2016) Von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, et al. Journal article Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study (2016) Woelber L, Griebel LF, Eulenburg C, Sehouli J, Jueckstock J, Hilpert F, De Gregorio N, et al. Journal article Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration (2016) Permuth JB, Reid B, Earp M, Chen YA, Monteiro ANA, Chen Z, Chenevix-Trench G, et al. Journal article Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study (2016) Gaß P, Fasching P, Fehm T, De Waal J, Rezai M, Baier B, Baake G, et al. Journal article Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study (2016) Dixon SC, Nagle CM, Thrift AP, Pharoah PDP, Pearce CL, Zheng W, Painter JN, et al. Journal article Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation (2016) Beckmann M, Sell C, Aydogdu M, Brucker SY, Fehm T, Janni W, Kreienberg R, et al. Journal article Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8) (2016) Emons G, Kurzeder C, Schmalfeldt B, Neuser P, De Gregorio N, Pfisterer J, Park-Simon TW, et al. Journal article Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer (2016) Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Doerk T, Hillemanns P, et al. Journal article International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus (2015) Moehler M, Baltin CT, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, et al. Journal article